Dr. Stanley Chang holds a Bachelor's degree in Medicine from National Taiwan University and a Ph.D. from the National Medical Laser Centre at University College London, UK. A board-certified urologist, Dr. Chang previously served as Professor and Chairman of the School of Medicine at Tzu Chi University, Director of the Department of Urology at Tzu Chi Hospital, and Attending Physician at National Taiwan University Hospital — bringing together a wealth of clinical and academic expertise.
Since founding Medigen Biotechnology Corp. in 2000, Dr. Chang has played a pivotal role in shaping the company's strategies, corporate operations, and international partnerships. Under his leadership, Medigen has evolved from a drug development startup into a diversified biomedical group with operations spanning new drug development, immunotherapy, vaccines and biologics, ophthalmic pharmaceuticals, precision medicine, and molecular diagnostics.
As the parent company of the group, Medigen Biotechnology Corp. now focuses on cancer drug development, immunotherapy, and investment management.
Since founding Medigen Biotechnology Corp. in 2000, Dr. Chang has played a pivotal role in shaping the company's strategies, corporate operations, and international partnerships. Under his leadership, Medigen has evolved from a drug development startup into a diversified biomedical group with operations spanning new drug development, immunotherapy, vaccines and biologics, ophthalmic pharmaceuticals, precision medicine, and molecular diagnostics.
As the parent company of the group, Medigen Biotechnology Corp. now focuses on cancer drug development, immunotherapy, and investment management.
Ms. Arlene Chiang holds an LL.M. from the University of Southern California, an M.B.A. in Intellectual Property from National Chengchi University, and a Master's degree in Agricultural Chemistry from National Taiwan University. Ms. Chiang previously served as an Associate Researcher in R&D at companies including Genemaster Biotechnology Corp., gaining hands-on experience in scientific research and development for over three years. Since joining Medigen Biotechnology Corp. in 2004, Ms. Chiang has overseen a wide range of functions including intellectual property management, legal affairs, project coordination, and corporate operations. She brings over 20 years of experience in the biomedical industry.
Ms. Jude Chen holds a Bachelor's degree in Nursing from Taipei Medical University. Ms. Chen previously served as a Clinical Nurse at Shin Kong Wu Ho-Su Memorial Hospital and as a Clinical Research Nurse at Glaxo Wellcome Taiwan Ltd., where she was involved in the clinical trial of lamivudine (Zeffix®), the first oral antiviral drug for hepatitis B, which was launched in Taiwan in 1999. Ms. Chen joined Medigen Biotechnology Corp. in 2001 and has been responsible for new drug development and clinical research. With 30 years of experience in biopharmaceuticals and clinical research, she brings extensive expertise to the field.
Ms. Patricia Chen holds a Bachelor's degree in Banking and Finance from Tamkang University. Ms. Chen previously worked in the underwriting departments of Hua Nan Securities and SinoPac Securities for over eight years, assisting companies in the IPO and listing process. Since joining Medigen Biotechnology Corp. in 2011, Ms. Chen has been responsible for financial management, accounting, internal auditing, and oversight of investment subsidiaries. With over 20 years of experience in finance and accounting, Ms. Chen brings solid expertise and industry insight to the company's financial operations.